Abstract
Background: Acute respiratory infections (ARIs) are commonly treated with antibiotics in outpatient settings, but many infections are caused by viruses and antibiotic treatment is therefore inappropriate. FebriDx®, a rapid point-of-care test that can differentiate viral from bacterial infections, can inform antibiotic treatment decisions.Objectives: The primary aim of this study is to conduct a literature-based US economic evaluation of a novel rapid point-of-care test, FebriDx®, that simultaneously measures two key infection biomarkers, C-reactive protein (CRP) and Myxovirus resistance protein A (MxA), to accurately differentiate viral from bacterial infection.Methods: A budget impact model was developed based on a review of published literature on antibiotic prescribing for ARIs in the United States. The model considers the cost of antibiotic treatment, antibiotic resistant infections, antibiotic-related adverse events, and point-of-care testing. These costs were extrapolated to estimate savings on a national level.Results: The expected national cost to treat ARIs under standard of care was US $8.25 billion, whereas the expected national cost of FebriDx point-of-care-guided ARI treatment was US $5.74 billion. Therefore, the expected national savings associated with FebriDx® rapid point-of-care testing was US $2.51 billion annually.Conclusions: FebriDx, a point of care test that can reliably aid in the differentiation of viral and bacterial infections, can reduce antibiotic misuse and, therefore, antibiotic resistant infections. This results in significant cost savings, driven primarily by the reduction in antibiotic resistant infections.
Highlights
Acute respiratory infections (ARIs) are common in outpatient settings and account for 41% of all antibiotics prescribed in ambulatory settings, about half of which are medically unnecessary.[1,2] Common Acute Respiratory Infection (ARI) treated in outpatient settings include sinusitis, otitis media, bronchitis, and pharyngitis
FebriDx, a point of care test that can reliably aid in the differentiation of viral and bacterial infections, can reduce antibiotic misuse and, antibiotic resistant infections
This results in significant cost savings, driven primarily by the reduction in antibiotic resistant infections
Summary
Acute respiratory infections (ARIs) are common in outpatient settings and account for 41% of all antibiotics prescribed in ambulatory settings, about half of which are medically unnecessary.[1,2] Common ARIs treated in outpatient settings include sinusitis, otitis media, bronchitis, and pharyngitis. Many of these infections are caused by viruses but are inappropriately treated with antibiotics.[1,3] This misuse of antibiotics has serious consequences, including the emergence of antibiotic resistant infections and drug-related adverse events. FebriDx®, a rapid point-of-care test that can differentiate viral from bacterial infections, can inform antibiotic treatment decisions
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
